VK2735 Maintenance Data: 22% Weight Loss, Up to 97% Maintained With Less Frequent Dosing
VKTX sits 56% above its 52-week low of $24.52 on elevated volume (2.2× avg).
Summary
Viking reported positive Phase 2 maintenance results for VK2735, its GLP-1/GIP agonist. The 17.5 mg weekly dose achieved 22% placebo-adjusted weight loss at Week 33. Switching to every-other-week dosing maintained up to 97% of that weight loss over three months, and monthly dosing maintained up to 90%. GI adverse events were similar to placebo during maintenance. The data supports flexible, less frequent dosing regimens that could improve patient convenience and adherence. Shares jumped on the news.
At the time of this announcement, VKTX was trading at $38.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $24.52 to $43.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.